Business Wire

Effepharm's UTHEVER ® NMN: 66 people Human Clinical Trial Data Published, NAD+/NADH Level increased 38% in 2 months

Share

Effepharm Ltd creatively launched a branded NMN ingredient to bring the purest and safest NMN ingredient around the world. UTHEVER® NMN has been clinically proven to be safe and to improve the NAD+/NADH level in the human body, thus realizing the anti-aging function.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005649/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Figure 1 https://www.frontiersin.org/articles/10.3389/fragi.2922.851698/full (Graphic: Business Wire)

On 5th May 2022, Frontiers in Aging, an authoritative international journal on aging mechanisms, published one NMN clinical trial report with new insights and more experience being brought into the field of longevity.

Frontiers in Aging, one of the largest and highest-cited publishers in the world, led and peer-reviewed by editorial boards of over 100,000 top researchers, agreed to publish UTHEVER® NMN’s human clinical trial report, which was reviewed by scientists, including professors at Harvard Medical School. This is the first time that Effepharm released detailed trial data to the public.

Compared with previous NMN clinical trials involving dozens of people, the number of Effepharm’s UTHEVER® clinical trial was up to 66 people which is more conspicuous. At the end of the study (day 60), the level of NAD+/NADH increased further by 38% from baseline in the UTHEVER® group, compared to a mere 14.3% rise in the placebo group which might be attributed to the placebo effect. HOMA (homeostatic model assessment), 6 minute walking endurance test and SF-36 questionnaire were assessed to show that UTHEVER® has the potential to improve the quality of life and boost the happiness of the subjects under the test conditions.

Moreover, Effepharm as one of the leading manufacturer of NMN, has finished the toxicology tests of Uthever, which proved that Uthever is non-mutagenic and has no acute and sub-chronic toxicity. Although the test results are not publicly available now, they have laid a solid foundation for the evaluation of the safety of UTHEVER® NMN.

Effepharm’s R&D Director Jianjun Yu said: “ The clinical trials of UTHEVER® NMN is to establish a more professional and scientific image, helping the downstream supplement brand side get more power to do product endorsement and give more confidence to end consumers. Up to now, more and more well-known supplement brands such as Prohealth Longevity® in the USA, Do Not Age in UK, Kenay® Agescience, AFEGE Anti-aging Shop, MoleQlar in EU., VitaNAD+ in Japan etc. are using UTHEVER® trademark and realized the co-branding effects.”

Dr. Yu also revealed that the first period of NMN clinical trials mainly aimed to verify the safety of UTHEVER® NMN, so we designed a lower dosage to some extent. In the next few years, we will consider to conduct more NMN function researches to explore the safety of larger doses of NMN and the effectiveness of related indications on which this trial data are based. Effepharm Ltd will also apply for FDA Affirmed GRAS on NMN, which means that NMN raw material through the food regulations of various countries has taken a milestone step.

Reference:

https://www.frontiersin.org/articles/10.3389/fragi.2022.851698/full

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Effepharm Ltd
marketing@effepharm.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p